Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Home - The Pharma Times | Pharma & Health Care News Portal
Friday, April 26, 2024

Indian Global Mental Health Expert, Vikram Patel Awarded The Prestigious John...

Toronto, May 19, 2019: The Gairdner Foundation today announced the 2019 Canada Gairdner Award laureates, recognising Goa and Boston-based Vikram Patel, Ph.D., F. Med.Sci., for...

Cipla announces Q2 FY 1213 Unaudited Financial Results

Mumbai, India: Cipla Limited (BSE: 500087, NSE : CIPLA) today announced its Unaudited Financial Results for the quarter ended September 30, 2012 (Q2).

Key Financial & Performance Highlights Q2 FY1213 vis-a-vis Q2 FY1112:

  • Gross revenues grew by 23.6% to Rs. 2220 cr, up from Rs. 1796 cr in Q2 FY1112
  • Operating margins grew by 57.7% to Rs. 677 cr, up from Rs. 429 cr in Q2 FY1112
  • Profit after tax grew by 61.8% to Rs. 500 cr during Q2 FY1213, up from Rs. 309 cr (Q2 FY1112)

Biotechnology

HCG Cancer Hospital completes Comprehensive Genomic Profi­ling (CGP) of 1000+ Cancer Patients

Bengaluru , August 22, 2023: Envisioned to drive a new standard of cancer care, Triesta Sciences, a Unit of HealthCare Global Enterprises Limited (HCG Cancer...

IT & Software Support

Appointments

Dinesh Chauhan stepping up as Chief Executive Officer of CORE Diagnostics

India, August 28, 2020: Gurgaon based CORE Diagnostics has announced that Dinesh Chauhan, the current Chief Operating Officer of the company, will be stepping...

Awards

Financial Results

Lincoln Pharmaceuticals Ltd reports 23% rise in the Standalone Net Profit at Rs.14.99 crore in Q1FY21

Becomes a Zero net-debt company paying its outstanding debt to the Financial Institution Net revenues...

Balaxi Pharmaceuticals reports continued solid growth in Q1 FY23

Revenue grows 42% in Q1FY23 Pharma Revenue in Latin America up 39%         ...

Approvals

Eisai’s Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer...

Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the...

Clinical Trails

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

Bulk Drug

Health Care

Alternative Medicine

Eye Care

Product News

LANXESS product Rely+On Virkon effective against coronavirus

Stronger demand in Asia and Europe Optimization of production capacities for increased delivery capability Effectiveness of Rely+On Virkon scientifically proven Mumbai, February 21, 2020:...

Media Partners

Spotlight

Investments

Packaging

Latest News

Medanta and Moolchand Introduce World-Class Cardiac Care in South Delhi

Launch Medanta-Moolchand Heart Centre  New Delhi, October 22, 2020: Furthering the vision of improving access to world-class healthcare for all, Medanta and Moolchand have collaborated...

GenWorks Health Celebrates 10th Foundation Day

New Delhi, February 23, 2024 :  GenWorks Health, a healthcare solutions provider celebrates and marks its 10th Foundation Day by announcing the launch of TECHGenworks to...

Maxivision Eye Hospital Expands to 3 New Centers in Hyderabad, Extending Its Reach for...

Hyderabad, October 18, 2023: Maxivision Eye Hospital, one of the leading names in eye care networks in Telangana and beyond, is thrilled to announce...

Eisai to Present Latest Data on Lemborexant at World Sleep Congress

Tokyo September 21, 2019: Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment...

Dental Care

Tips to maintain oral health!

By Dr.MS Prasad, Dental Surgeon, Columbia Asia Referral Hospital Yeshwanthpur It has been said that a person’s real happiness begins from the plate and is...

Hospital Management

Drug Discovery & Development

Drug Discovery Unit (DDU), University of Dundee Licenses GVK BIO Online SAR Database (GOSTAR)

Hyderabad, Andhra Pradesh, India, Wednesday, April 10, 2013 -- (Business Wire India) -- GVK Biosciences (GVK BIO) today announced that it has licensed its Online SAR Database - GOSTAR to the Drug Discovery Unit (DDU) at the University of Dundee. GOSTAR, a manually curated database, has been developed over the span of a decade by a team comprising of more than 200 curators. The product issued globally in various areas such as pharmaceuticals, academics, government sectors, apart from numerous publications that cite the data contained in GOSTAR. GOSTAR contains over 6 million compounds manually curated through the screening of over 2 million patents and 400,000 journals and it also contains more than 18 million quantitative SAR points.

Suppliers

Technology

Batteries Designed for Space Robots Are Now Being Used in Hospitals

New Delhi, September 29, 2020: It’s important that during a space mission astronaut have reliable and anti-flammable lithium-ion batteries to assist them in maintaining...

Companies

Lupin appoints Ms. Christine Mundkur as an Independent Director

Mumbai, April 02, 2019: Pharma major Lupin Limited (Lupin) announced today the appointment of Ms. Christine Mundkur as an Independent Director with...

Marketing

Our Partners

Machinery & Equipments